Tamoxifen, screening and new oestrogen receptor modulators

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 15, Issue 3, 2001, Pages 365-380

  Neven, Patrick ^a   Vergote, Ignace ^b  

^a Saint Jean Clinic of Brussels   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Endometrial effects; Screening; SERMs; Tamoxifen; Uterus

Indexed keywords

1,1,2 TRIPHENYLETHYLENE DERIVATIVE; 4 (1,2 DIPHENYL 1 BUTENYL)CINNAMIC ACID; 4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; ACOLBIFENE; ANTIESTROGEN; ARZOXIFENE; BENZOPYRAN DERIVATIVE; BENZOTHIOPHENE DERIVATIVE; CENTCHROMAN; DROLOXIFENE; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; GW 5836; IDOXIFENE; INDOLE DERIVATIVE; LASOFOXIFENE; NAFOXIDINE; NAPHTHALENE DERIVATIVE; PHYTOESTROGEN; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE; TRIOXIFENE; UNCLASSIFIED DRUG; ZINDOXIFENE;

BONE; BREAST; BREAST CANCER; CANCER MORTALITY; CANCER STAGING; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG ACTIVITY; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; DRUG USE; EARLY DIAGNOSIS; ENDOMETRIOSIS; ENDOMETRIUM ATROPHY; FOLLOW UP; HORMONE INHIBITION; HORMONE SUBSTITUTION; HUMAN; HYSTEROSCOPY; INCIDENCE; MEDICAL ASSESSMENT; POPULATION RISK; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SECONDARY PREVENTION; TREATMENT OUTCOME; ULTRASOUND; UTERUS CANCER; UTERUS CAVITY; UTERUS DISEASE;

EID: 0034929809     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1053/beog.2001.0182     Document Type: Article

References (71)

1. Tamoxifen for early breast cancer: An overview of the randomised trials
2. Molecular basis of agonism and antagonism in the oestrogen receptor
3. Tamoxifen for prevention of breast cancer: Report of the NSABP-PI study
4. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
5. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women
6. Gynaecological effects of tamoxifen
7. Tamoxifen and the uterus and endometrium
8. Hysteroscopic follow-up during tamoxifen treatment
9. Longitudinal hysteroscopic follow-up during tamoxifen treatment
10. Malignant endometrial polyps in postmenopausal breast cancer tamoxifen-treated patients
11. Endometrial cancer in polyps associated with tamoxifen use
12. Adjuvant tamoxifen in early breast cancer: Occurence of new primary cancers
13. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer
14. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project B-14
15. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis
16. Tamoxifen therapy for breast cancer and endometrial cancer risk
17. Controversies regarding tamoxifen and uterine carcinoma
18. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial
19. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer
20. Uterine carcinosarcomas in patients receiving tamoxifen. A report of 19 cases
21. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer
22. Unusual ultrasonographic appearance of the uterus in women receiving tamoxifen
23. Pathology of endometrium treated with tamoxifen
24. Uterine effects of tamoxifen: A prospective study
25. The effect of tamoxifen on endometrial thickness and endometrial histology
26. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening
27. Thickened endometrium caused by tamoxifen returns to normal following tamoxifen cessation
28. Ultrasonographic measurements of endometrial changes following discontinuation of tamoxifen treatment in postmenopausal breast cancer patients
29. Endometrial carcinoma
30. Screening for endometrial cancer in patients receiving tamoxifen for breast cancer
31. Surveillance of endometrial cancer in women receiving tamoxifen
32. Modulation of endometrial steroid receptors and growth regulatory genes by tamoxifen
33. Tamoxifen and the uterus. Editorial
34. Uterine side effects of tamoxifen: A need for systematic pretreatment screening
35. The ATAC (arimidex, tamoxifen, alone or in combination) adjuvant breast cancer trial in postmenopausal women: Baseline endometrial sub-protocol data
36. A randomized trial on the use of ultrasonography or office hysteroscopy for endometrial assessment in postmenopausal patients with breast cancer who were treated with tamoxifen
37. Transvaginal endometrial sonography in postmenopausal women taking tamoxifen
38. Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease
39. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities
40. The predictive value of endometrial thickness in patients receiving tamoxifen
41. Endometrial thickeness in tamoxifen-treated patients: An independent predictor of endometrial disease
42. Significance of endovaginal ultrasonography in assessing tamoxifen-associated changes of the endometrium. A prospective study
43. Changes mimicking endometrial neoplasia in tamoxifen-treated women with breast cancer: A transvaginal Doppler study
44. Steroid receptor expression in endometria from women treated with tamoxifen
45. Failure of megesterol acetate to reverse tamoxifen induced endometrial neoplasia
46. The effects of norethisterone on endometrial abnormalities identified by transvaginal ultrasound screening of healthy post-menopausal women on tamoxifen or placebo
47. Should tamoxifen users be screened for endometrial lesions?
48. Tamoxifen and endometrial cancer
49. Tamoxifen does not promote tumour progression in surgically treated endometrial cancer
50. Raloxifene is a tissue-specific anti-estrogen that blocks tamoxifen or estrogen stimulated uterotrophic effects
51. Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women
52. Tamoxifen activation of the estrogen receptor/AP-I pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens
53. The estrogen receptor enhances AP-I activity by two distinct mechanisms with different requirements for receptor transactivation functions
54. Cloning of a novel receptor expressed in rat prostate and ovary
55. Differential ligand activation of estrogen receptors ERa and ERb at API sites
56. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women
57. Uterine safety considerations for selective estrogen receptor modulators
58. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium
59. Uterine effects of raloxifene in comparison with continuous combined hormone replacement therapy in postmenopausal women
60. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
61. Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60
62. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
63. The effect of raloxifene on risk of breast cancer in postmenopausal women
64. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients
65. Effects of CP-336,156 a new nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus, and body composition in rat models
66. EM-652 (SCH 57068), a third generation SERM acting as pure antioestrogen in the mammary gland and endometrium
67. LY 353381 HCL: An improved benzothiophene analog with bone efficacy complementary to parathyroid hormone
68. Discovery and synthesis of a novel highly potent SERM
69. The role of isoflavones in menopausal health: Consensus opinion of the North American Menopause Society
70. Reproductive actions of phytoestrogens